国产精品av在线观看不_日韩久久美女毛片_黄色网站在线性爱视频_9691精品人妻无码久久久_成年AV免费网址大全超清_亚洲aⅴ天堂无码_曰本裸色私人影院噜噜噜影院_另类视频无码视频国产精品_网红三级在线播放_美腿丝袜在线观看

Entries by

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TASURGRATINIB FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSION

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, “tasurgratinib”) for biliary tract cancer with?FGFR2?gene fusion. In Japan, tasurgratinib has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with?FGFR2?gene fusion by the Ministry of Health, Labour and Welfare, (MHLW). Under this system, this application will be subject to priority review.

2023/12/18 by

“LEQEMBI? Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20

TOKYO and CAMBRIDGE, Mass., December 13, 2023?–?Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI??Intravenous Infusion” (200 mg, 500mg, lecanemab) will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance (NHI) Drug Price List.

2023/12/13 by

APPLICATION SUBMITTED FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA? IN COMBINATION WITH KEYTRUDA? AS A TREATMENT FOR ADVANCED RENAL CELL CARCINOMA IN JAPAN

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, President: Kyle Tattle, “MSD”), a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA? (generic name: lenvatinib mesylate), in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s KEYTRUDA? (generic name: pembrolizumab) as a treatment for patients with advanced renal cell carcinoma (RCC). This is the first application to be submitted in Japan for this combination therapy.

2021/3/31 by

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries

KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Shigeru Ogihara, “KYORIN”), a subsidiary of KYORIN Holdings, Inc. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara), and Eisai Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, CEO: Haruo Naito, “Eisai”) have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. Based on this agreement, Eisai will acquire exclusive development and marketing rights from KYORIN for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.

2021/3/31 by

EUROPEAN MEDICINES AGENCY ACCEPTS THE MARKETING AUTHORISATION APPLICATIONS FOR TWO ADDITIONAL INDICATIONS OF ANTI CANCER AGENT LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB AS A TREATMENT FOR ADVANCED RENAL CELL CARCINOMA AND ADVANCED ENDOMETRIAL CARCINOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate (product name: LENVIMA? / Kisplyx?, “l(fā)envatinib”), in combination with anti-PD-1 therapy pembrolizumab (brand name: KEYTRUDA?), developed by Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) as a treatment f or patients with advanced renal cell carcinoma (RCC) and advanced endometrial carcinoma (EC), respectively.

2021/3/30 by

Eisai China Policy on Submission of Ideas: 1. Eisai China Holdings Ltd., its affiliates and subsidiaries (collectively, ” Eisai China”) are committed to protecting the privacy of the information collected from external individuals and organizations through Eisai China online opportunity submission process. Information here refers to personal identifiable information and other personal data, as well […]

2021/2/26 by

Contact Us

Eisai China Holdings Ltd. / Eisai China Inc.   Shanghai?Branch Address: 39-40th Floor, Park Place, No.1601 Nanjing Xi Road, Shanghai, P.R.C Tel: 021–24192888????Fax: 021–24192891????Zip Code: 200040 Suzhou Factory Address: 168# Xingpu Road,Suzhou Industrial Park,JiangSu Province P.R.C Tel: 86-512-69566776???? Fax: 86-512-62576776???? Zip Code: 215126 Beijing Branch Address: 2303-2306 Room, 23th Floor, World Wealth Tower, No.A6 JianGuoMenWai […]

2021/2/23 by

Accessibility features of the site

? ? ? ? Eisai China is committed to making this website accessible to the broadest possible audience, regardless of technology or physical capability. To this end, we are working constantly to improve the overall usability of the site, using many of the existing international standards for accessibility on the Internet as guidelines. Images: ? […]

2021/2/19 /0 Comments/by

Legal Notice

Legal Notice of Eisai China Inc. Website Please read the following legal notice carefully prior to using the corporate website (“the Website”) of Eisai China Inc. (“Eisai”), which includes Copyrights, Trademarks and Domain Name, Privacy, Disclaimers, Links, Applicable Laws and Versions. By accessing the Website, you agree and accept all terms of this legal notice, […]

2021/2/19 /0 Comments/by